Jump to contents

Researcher Information

last modified:2018/04/13

Professor MORISHITA Eriko

Faculty, Affiliation

Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences

College and School Educational Field

Division of Health Sciences, Graduate School of Medical Science
Division of Health Sciences,Graduate School of Medical Science
Department of Laboratory Sciences,School of Health Sciences, College of Medical, Pharmaceutical and Health Sciences

Laboratory

 TEL:076-265-2606 FAX:

Academic Background

【Academic background(Bachelor's Degree)】
Nippon Medical School 198603
【Degree】
Medical doctor

Career

Kanazawa University(1989/11/01-1993/03/31)
Kanazawa University(1993/04/01-1994/03/31)
Kanazawa University(1994/04/01-1997/03/31)
Kanazawa University(1997/04/01-)

Year & Month of Birth

Academic Society

the Japanese Society of Hematology
Japanese Society of Internal Medicine
The Japanese Society on Thrombosis and Hemostasis
Japan Thrombosis and Hemostasis
Japan Atherosclerosis Society
Japanese Society of Laboratory Medicine
The Japanese Society of Clinical Hematology

The Japanese Society of Laboratory Medicine




Award

Specialities

Hematology、Laboratory medicine

Speciality Keywords

Hematology, Thrombosis and Hematology, congenital thormbophilia, antiphosopholipid syndrome, Disseminated Intravascular Coagulation Syndrome

Research Themes

Genetic analysis and expression studiesin congenital cogulation factor deficiencies and coagulation inhibitor deficiencies

I conduct genetic analysis of individuals with congenital coagulation factor deficiencies and coagulation inhibitor deficiencies, and their families, to identify the mutation sites. I have analyzed coagulation factor deficiencies in terms of prothrombin, factors VII, X, XI, XII, and prekallikrein, as well as coagulation inhibitor deficiencies in terms of protein C, protein S(PS), antithrombin, and have continuously demonstrated new mutation sites that had not been reported internationally. Further, I generate abnormal molecules with a recombinant DNA procedure and conduct their functional analysis. PS deficiency is important also as a cause of habitual abortion, and the demand for its genetic analysis will likely increase.

Mechanism of thrombosis in arteriovascular disease

With regard to arteriosclerosis and thrombosis, I examine hyperlipidemia and thrombotic tendency with molecular markers and manifestation of monocytic coagulation−fibrinolytic factors upon lipoprotein stimulus. Recently, I have been conducting research on the effect of an antihypercholesterolemia, HMG-CoA reductase inhibitor (statin), on coagulation−fibrinolytic system as a pleiotropic effect, and have clarified that statin down-regulate monocytic tissue factors in vascular endothelial cells and the manifestation of a coagulation−fibrinolytic factor PAI-1, while down-regulate the manifestation of anticaking factor TFPI, thereby demonstrating the potential for anti-thrombogenicity effect.

Mechanism of thrombosis in arteriovascular disease

Congenital thrombophilia

antiphospholipid syndrome

Disseminated Intravascular Syndrome

Crosstalk betwenn inflammation and thrombosis

Mechanism of thormbotic formation in Hemolytic Uremic Syndrome

Antithrobotic efests of hemeoxygenase-1

Books

  •  Asakura H, Takahashi Y, Kubo A, Ontachi Y, Hayashi T, Omote M, Arahata M, Kadohira Y, Maekawa M, Yamazaki M, Morishita E, Takami A, Yoshida T, Miyamoto K, Nakao S Immunoglobulin preparations attenuate organ dysfunction and hemostatic abnormality by suppressing the production of cytokines in lipopolysaccharide-induced disseminated intravascular coagulation in rats 34 9 2421-5 2006/09
  •  Ontachi Y, Morishita E, Nakao S, etc No interplay between the pathways mediating coagulation and inflammation in tissue factor-induced disseminated intravascular coagulation in rats 34 10 2646-2650 2006/10
  •  Asakura H, Asamura R, Ontachi Y, Hayashi T, Yamazaki M, Morishita E, Miyamoto KI, Nakao S Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS-induced DIC model rats 3 5 1050-5 2005/05
  •  Recent Progress in Blood Coagulation and Fibrinolysis Elsevier 1998/01

Papers

  •  Gene analysis of inherited antithrombin deficiency and functional analysis of abnormal antithrombin protein (N87D).  Kamijima S, Sekiya A, Takata M, Nakano H, Murakami M, Nakazato T, Asakura H, Morishita E.  Int J Hematol. 107 4 490-494 2018/04/01
  •  Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban.  Kadohira Y, Yamada S, Matsuura E, Hayashi T, Morishita E, Nakao S, Asakura H.  Intern Med. 56 21 2913-2917 2017/11/01
  •  Factor XI deficiency as a result of a novel Tyr347Stop nonsense mutation in an elderly Japanese woman. Ando J, Masuda A, Iizuka K, Ochiai T, Shingai N, Yasuda H, Homma Y, Kobayashi E, Morishita E, Komatsu N.  Geriatr Gerontol Int. 17 6 1029-1031 2017/06/01
  •  The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. Sugiura-Ogasawara M, Omae Y, Kawashima M, Toyo-Oka L, Khor SS, Sawai H, Horita T, Atsumi T, Murashima A, Fujita D, Fujita T, Morimoto S, Morishita E, Katsuragi S, Kitaori T, Katano K, Ozaki Y, Tokunaga K.  J Hum Genet. 62 9 831-838 2017/09/01
  •  A case of aortic aneurysm-associated DIC that responded well to a switch from warfarin to rivaroxaban. Kadohira Y, Matsuura E, Hayashi T, Morishita E, Nakao S, Asakura H. Int Med. 56 21 2913-2917 2017/11/01

show all

  •  Thrombosis prediction based on reference ranges of coagulation-related markers in different stages of pregnancy.  Sekiya A, Hayashi T, Kadohira Y, Shibayama M, Tsuda T, Jin X, Nomoto H, Asakura H, Wada T, Ohtake S, Morishita E. Clin Appl Thromb Hemost. 23 7 844-850 2017/10/01
  •  Expression of annexin II in human atherosclerotic abdominal aortic aneurysms. Hayashi T, Morishita E, Ohtake H, Oda Y, Ohta K, Arahata M, Kadohira Y, Maekawa M, Ontachi Y, Yamazaki M, Asakura H, Takami A, Nakao S THROMBOSIS RESEARCH 123(2)  274-80 2009/03
  •  Hemostatic management of surgery for imperforate anus in a patient with 13q deletion syndrome with combined deficiency of factors VII and X. Kurosawa H, Suzumura H, Okuya M, Fukushima K, Sugita K, Fujiwara T, Morishita E, Yoshioka A, Takamiya O, Arisaka O 15(1) 398-400 2009/01
  •  A case of factor X (FX) deficiency due to novel mutation V196M, FX Hofu. 1) Shinohara K, Adachi M, Matsui K, Matsuda K, Nagaya S, Morishita E INTERNATIONAL JOURNAL OF HEMATOLOGY 87 3 256-259 2008/03
  •  Increased macrophage colony-stimulating factor levels in patients with Graves' disease. Morishita E, Sekiya A, Hayashi T, Kadohira Y, Maekawa M, Yamazaki M, Asakura H, Nakao S, Ohtake S INTERNATIONAL JOURNAL OF HEMATOLOGY 88(3)  272-7 2008/03
  •  Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report. Hayashi T, Morishita E, Ontachi Y, Yamazaki M, Asakura H, Yoshida T, Nakao S AMERICAN JOURNAL OF HEMATOLOGY 81 2 121-123 2006/02
  •  Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers. Omote M, Asakura H, Takamichi S, Shibayama M, Yoshida T, Kadohira Y, Maekawa M, Yamazaki M, Morishita E, Nakao S, Wada T 123(2) 390-5 2008/02
  •  Beneficial effects of urokinase on lipopolysaccharide-induced disseminated intravascular coagulation in rats: focus on organ function and endothelin levels 93 4 724-8 2005/04
  •  Effects of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm Ontachi Y, Asakura H, Morishita E, et al Circulation Journal 69 9 1150-1153 2005/09
  •  Role of fibrinolysis in tissue-factor-induced disseminated intravascular coagulation in rats - an effect of tranexamic acid Asakura H, Sano Y, Yamazaki M, Morishita E, et al HAEMATOLOGICA 89 6 757-8 2004/06
  •  Antithrombotic role of nitric oxide in rats under physiological conditions Asakura H, Okudaira M, Ontachi Y, Mizutani T, Omote M, Yoshida T, Kaneda M, Yamazaki M, Morishita E, et al THROMBOSIS AND HAEMOSTASIS 91 71-5 2004
  •  Beneficial effect of low-molecular-weight heparin against lipopolysaccharide-induced disseminated intravascular coagulation in rats is abolished by coadministrastion of tranexamic acid Asakura H, Sano Y, Yoshida T, Omote M, Ontachi Y, Mizutani T, Yamazaki M, Morishita E, et al INTENSIVE CARE MEDICINE 30 1950-1955 2004
  •  An idiopathic skin eruption resembling a butterfly rash in a septic patient with disseminated intravascular coagulation following bone marrow transplantation Ontachi Y, Asakura H, Funada H, Takami A, Saito M, Morishita E, etal BLOOD COAGULATION & FIBRINOLYSIS 15 3 255-259 2004/03
  •  Relationship between endothelin and the pathophysiology of tissue factor-induced and lipopolysaccharide-induced disseminated intravascular coagulation in rats: a study examining the effect of an endothelin receptor antagonist Suga U, Asakura H, Yoshida T, Omote M, Ontachi Y, Mizutani T, Yamazaki M, Morishita E, et al BLOOD COAGULATION & FIBRINOLYSIS 15 593-598 2004
  •  Significant of decreased plasma D-Dimer levels following lipoplysaccharide-induced disseminated intravascular coagulation in rats Asakura H, Sano Y, Omote M, Yoshida T, Ontachi Y, Mizutani T, Kaneda M, Yamazaki M, Morishita E, et al INTERNATIONAL JOURNAL OF HEMATOLOGY 79 394-9 2004
  •  All-trans retinoic acid is partially effective against lipopolysaccharide-induced but not against tissue-factor-induced DIC in rat models. BLOOD COAGULATION & FIBRINOLYSIS 12 4 301-306 2001/06
  •  An enhanced fibrinolysis prevents the development of multiple organ failure in DIC in spite of much activation of blood coagulation. CRITICAL CARE MEDICINE 29 6 1164-1168 2001/06
  •  Beneficial effect of the active form of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models. THROMBOSIS AND HAEMOSTASIS 85 287-290 2001/02
  •  Depressed plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with DIC. EUROPEAN JOURNAL OF HAEMATOLOGY 67 170-175 2001/06
  •  Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia 9 1 72-78 2002/01
  •  Marked difference in pathophysiology between tissue factor-and lipopolysaccharide-induced disseminated intravascular coagulation models in rats. CRITICAL CARE MEDICINE 30 1 161-164 2002/11
  •  Depressed plasma activity of plasminogen or a2-plasmin inhibitor is not due to consumption coagulopathy in septic patients with DIC. Blood Coagulation and Fibrinolysis 12 4 275-281 2001/06
  •  Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. BLOOD COAGULATION & FIBRINOLYSIS 12 1 1-8 2001/01
  •  Elevated plasma levels of free-form of TFPI in hypercholesterolemic patients. ATHEROSCLEROSIS 154 1 203-212 2001/01
  •  Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression. BLOOD COAGULATION & FIBRINOLYSIS 10 6 321-330 1999/09
  •  Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease. Thromb Haemost 79 5 919-923 1998/05
  •  Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. OSTEOPOROSIS INTERNATIONAL 12 996-1000 2001/12
  •  One missence mutation in the factor X gene causing factor X deficiency (factor X Kanazawa) INTERNATIONAL JOURNAL OF HEMATOLOGY 73 3 390-392 2001/04
  •  Short-term effects of fluvastatin, a HMG-CoA reductase inhibitor, on coagulation and the fibrinolytic system in patientswith hypercholesterolemia. INTERNATIONAL JOURNAL OF HEMATOLOGY 69 4 274-276 1999/06
  •  Treatment of DIC with all-trans retinoic acid in an endotoxin-induced rat. SEMINARS IN THROMBOSIS AND HEMOSTASIS 24 3 227-231 1998/12
  •  Prothrombin fragment1+2 mesures treatment effect in patients with antiphospholipid syndrome. 91 3 121-128 1998/08
  •  Prophylactic administration of prothrombin complex concentrates for congenital prothrombin deficiency with a novel frameshift mutation, prothrombin saitama Seki, Masafumi; Koh, Katsuyoshi; Inoue, Takeshi; Tomita, Yuzo; Kato, Motohiro; Shimizu, Masaki; Morishita, Eriko; Hanada, Ryoji Pediatric Blood and Cancer 60 3 503-505 2013/03/01 
  •  Antithrombin deficiency in three Japanese families: One novel and two reported point mutations in the antithrombin gene Maruyama, Keiko; Morishita, Eriko; Karato, Megumi; Kadono, Tadaaki; Sekiya, Akiko; Goto, Yukie; Sato, Tomomi; Nomoto, Haruka; Omi, Wataru; Tsuzura, Sachie; Imai, Hidenori; Asakura, Hidesaku; Ohtake, Shigeki; Nakao, Shinji Thrombosis Research 132 2 e118-e123 2013/08/01 
  •  Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm: A case report Hayashi, Tomoe; Nakagawa, Noriharu; Kadohira, Yasuko; Morishita, Eriko; Asakura, Hidesaku Annals of Internal Medicine 161 2 158-159 2014/07/15 
  •  Two case reports of inherited antithrombin deficiency: a novel frameshift mutation and a large deletion including all seven exons detected using two methods Sekiya, Akiko;Morishita, Eriko;Karato, Megumi;Maruyama, Keiko;Shimogawara, Itsumi;Omote, Mika;Wakugawa, Yoshiyuki;Shinohara, Moeko;Hayashi, Tomoe;Kadohira, Yasuko;Asakura, Hidesaku;Nakao, Shinji;Ohtake, Shigeki INTERNATIONAL JOURNAL OF HEMATOLOGY 93 2 216-219 2011
  •  A case of acquired FXIII deficiency with severe bleeding symptoms Hayashi, Tomoe; Kadohira, Yasuko; Morishita, Eriko; Asakura, Hidesaku; Souri, Masayoshi; Ichinose, Akitada Haemophilia 18 4 618-620 2012/07/01 
  •  Plasma levels of platelet-derived microparticles in patients with obstructive sleep apnea syndrome Maruyama, Keiko; Morishita, Eriko; Sekiya, Akiko; Omote, Mika; Kadono, Tadaaki; Asakura, Hidesaku; Hashimoto, Masami; Kobayashi, Masako; Nakatsumi, Yasuto; Takada, Shigeo; Ohtake, Shigeki Journal of Atherosclerosis and Thrombosis 19 1 98-104 2012/02/09 
  •  Plasma levels of platelet-derived microparticles are increased after anaerobic exercise in healthy subjects Maruyama, Keiko; Kadono, Tadaaki; Morishita, Eriko Journal of Atherosclerosis and Thrombosis 19 6 585-587 2012/07/11 
  •  New quantitative total protein S-assay system for diagnosing protein S type II deficiency: Clinical application of the screening system for protein S type II deficiency Tsuda, Tomohide; Jin, Xiuri; Tsuda, Hiroko; Ieko, Masahiro; Morishita, Eriko; Adachi, Tomoko; Hamasaki, Naotaka Blood Coagulation and Fibrinolysis 23 1 56-63 2012/01/01 
  •  Carbon monoxide (CO)-releasing molecule-derived CO regulates tissue factor and plasminogen activator inhibitor type 1 in human endothelial cells Maruyama, Keiko; Morishita, Eriko; Yuno, Takeo; Sekiya, Akiko; Asakura, Hidesaku; Ohtake, Shigeki; Yachie, Akihiro Thrombosis Research 130 3 e188-e193 2012/09/01 
  •  Fluvastatin upregulates the expression of tissue factor pathway inhibitor in human umbilical vein endothelial cells. Sekiya A, Morishita E, Maruyama K, Torishima H, Ohtake S J Atheroscler Thromb 2015
  •  A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation Int J Hematol 2015/10
  •  ELISA-based detection system for protein S K196E mutation, a genetic risk factor for venous thromboembolism PLoS One 2015
  •  Late onset thrombosis in two Japanese patients with compound heterozygote protein S deficiency Thromb Res 2015
  •  Fluvastatin upregulates the expression of tissue factor pathway inhibitor in human umbilical vein endothelial cells J Atheroscler Thromb 2015
  •  Gene analysis of six cases of congenital protein S deficiency and functional analysis of protein S mutations (A139V, C449F, R451Q, C475F, A525V and D599TfsTer13 Thromb Res 2017
  •  Causative genetic mutations for antithrombin deficiency and their clinical background among Japanese patients Int J Hematol 2016
  •  Thrombosis prediction based on reference ranges of coagulation-related markers in different stages of pregnancy. Clinical and Applied   Clinical and Applied Thrombosis/Hemostasis  DOI: 10.1177. 2016
  •  Familial discrepancy of clinical outcomes associated with fibrinogen Dorfen: A case of huge genital hematoma after episiotomy J Obstet Gynaecol Res 42 6 722-725 2016
  •  Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, Morita Y, Nishiwaki K, Ninomiya H, Gotoh A, Imashuku S, Urabe A, Shichishima T, Nishimura J, Kanakura Y  Int J Hematol 103 6 703-712 2016
  •  A case of aortic aneurysm-associated DIC that responded well to a switch from warfarin to rivaroxaban Int Med 2016
  •  Fulminant bilateral cerebral infarction caused by paradoxical embolism in a patient with protein S Ala525Val substitution Yoshikawa Y, Kitayama J, Ishikawa H, Nakamura A, Taniguchi F, Morishita E, Ago T, Nakane H, Kitazono  Neurology and Clinical Neuroscience 2015/01/09
  •  Diagnosis and treatment of inherited thrombophilia. 森下英理子 臨床血液 58 7 866-874 2017
  •  DOAC療法が先天性血栓性素因に及ぼす影響 門平靖子, 森下英理子 血栓止血誌 29 1 20-27 2018/01
  •  周術期に留意すべき凝固異常 第1回 先天性血栓性素因~先天性プロテインC・プロテインS欠損症 森下英理子 Thrombosis Medicine 2017年12月号 2017/12
  •  動脈・静脈の疾患(上)-最近の診断・治療動向-静脈疾患の検査 森下英理子 日本臨床 75 増刊号4 196-200 2017
  •  遺伝性血栓性素因の診断と治療 森下英理子 臨床血液 58 7 866-874 2017

Conference Presentations

  • 十全大補湯によるNK細胞機能増強効果の検討(conference:第57回日本臨床検査医学会東海・北陸支部総会、第336回日本臨床化学会東海・北陸支部例会)(2018/03/11)
  • ヘパリンからDOACへの変更に伴い治療効果が著変下血管腫に伴う慢性DICの一例(conference:第18回TTMフォーラム)(2018/03/03)
  • 直接経口抗凝固薬が血中アンチトロンビン、プロテインC、プロテインS活性測定値に与える影響(conference:第79回日本血液学会学術集会)(2017/10/20)
  • 十全大補湯によるNK細胞機能増強効果の検討(conference:第42回北陸臨床病理集談会)(2017/09/02)
  • ヒト iPS 細胞由来造血幹細胞を用いた6pLOH マウスモデルの作製(conference:第42回北陸臨床病理集談会)(2017/09/02)

show all

  • 先天性プロテインC欠損症の遺伝子解析および異常プロテインC蛋白(K437E)の機能解析(conference:第42回北陸臨床病理集談会)(2017/09/02)
  • EliAによる自動分析装置を用いた抗リン脂質抗体価測定の有用性(conference:第18回日本検査血液学会学術集会)(2017/07/22)
  • 当院で経験した第V因子インヒビター4例の特徴.(conference:第39回日本血栓止血学会学術集会)(2017/06/08)
  • Possible therapeutics for antiphospholipid antibody related thrombocytopenia:A systemic review and meta-analysis(conference:The American College of Rheumatology/Association of Rheumatology Health Professionals 2017 annual meeting.)(2017/11/03)
  • 先天性血友病の診断と治療(conference:中外製薬研修会)(2018/03/14)
  • 静脈血栓塞栓症の成因と治療―悪性腫瘍を中心にー(conference:Cancer VTE Seminar in Yokohama)(2018/03/01)
  • 静脈血栓塞栓症の成因と治療(conference:第五回抗凝固療法セミナー)(2018/02/26)
  • 基礎から学ぶ播種性血管内凝固症候群(DIC)(conference:血液・凝固セミナー)(2018/02/20)
  • 遺伝性血栓性素因と検査(conference:石川県医師会臨床検査制度管理調査合同報告会)(2018/02/11)
  • 静脈血栓塞栓症の成因と治療,骨髄腫治療のトータルマネジメント~VTEとSREへの対応~(2018/02/01)
  • 静脈血栓塞栓症の成因と治療(conference:緩和ケアカンファレンス)(2018/01/25)
  • 知っておきたい静脈血栓塞栓症の傾向と対策(conference:血栓塞栓症を考える会)(2017/04/06)
  • 静脈血栓塞栓症の病態・診断・治療~悪性腫瘍および先天性血栓性素因を中心に~(conference:iMET in KOBE)(2017/06/22)
  • APTT延長を認めたらどんな病態を考えますか?(conference:45nd SEKISUI Coagulation Seminar in Ariake)(2017/07/01)
  • 静脈血栓塞栓症の病態・診断・治療~悪性腫瘍および先天性血栓性素因を中心に~(conference:東葛HEART研究会)(2017/11/14)
  • 悪性腫瘍に関連する血栓症(conference:第17回群馬血栓止血研究会)(2017/11/16)
  • 静脈血栓塞栓症の病態・診断・治療~悪性腫瘍および先天性血栓性素因を中心に~(conference:VTE BOARD FORUM 2017)(2017/12/04)
  • 播種性血管内凝固症候群(DIC)と輸血(conference:愛知県臨床検査技師輸血研究班講演会)(2017/12/09)
  • 先天性血栓性素因の病態と解釈~臨床検査技師の視点から~(conference:第18回日本検査血液学会学術集会)(2017/07/22)
  • 先天性第X因子欠乏症5症例のphenotypeおよびgenotype(conference:第12回日本血栓止血学会学術標準化委員会(SSC))(2018/02/10)
  • 部会活動の紹介ならびに指定難病「特発性血栓症」の診断に際しての問題点(conference:第12回日本血栓止血学会学術標準化委員会(SSC))(2018/02/10)
  • 血液の難病に挑む~出血と血栓に関連する血液難病について~(conference:厚生労働科学研究費補助金難治性疾患政策研究事業 血液凝固異常症等に関する研究班)(2018/02/03)
  • Development of ELISA system for detection of Protein S K196E mutation, a genetic risk factor for venous thromboembolism.(conference:ISTH)(2015/06/20)
  • Thrombomodulin has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies(conference:56th American Society of Hematoogy Annual Meeting)(2014/12/05)
  • An uncommon case of deep venous thrombosis and pulmonary thromboembolism in a juvenile with compound heterozygous congenital protein S deficiency(conference:XXVI World Congress of the International Union of Angiology)(2014/08/10)
  • A genetic variant in the CD53 intron functiononally predicts transplant outcomes after HLA-matched unrelated bone marrow transplantation(conference:第18回欧州血液学会(EHA))(2013/06/13)
  • Management of pregnancy in paroxysmal nocturnal hemoglobinuria(conference:55rd ASH Annual Meeting)(2013/12/07)

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○「抗リン脂質抗体関連血小板減少症の病態解明と治療指針の構築に関する研究」(2015-2016) 
○「生体侵襲時におけるヘムオキシゲナーゼ1を介する血栓形成制御機構の解明」(2006-2008) 
○「身近に感じる血液のしくみを一緒に体験してみよう」(2015-) 
○「身近に感じる血液のしくみを一緒に体験してみよう」(2014-) 
○「ヘムオキシゲナーゼー1が造血幹細胞移植治療成績におよぼす改善効果の解明と新規治療戦略」(2015-) 
○「ヘムオキシゲナーゼー1が造血幹細胞移植後治療成績におよぼす効果と新規治療戦略」(2015-2017) 
○「血液凝固異常症等に関する調査研究班」(主任研究者 村田満)」(2014-2016) 
○「ヘムオキシゲナ-ゼ-1と同種造血幹細胞移植後転帰の関連性および新規治療戦略」(2012-2014) 
○「ヒムオキシゲナーゼ-1(HO-1)が凝固・線容系因子の発現調節に果たす役割の解明」(2007-2009) 
○「生体侵襲時におけるヘムオキシゲナーゼ-1を介する血栓形成制御機構の解明」(2009-2011) 
○「生体侵襲時におけるヘムオキシゲナーゼ1を介する血栓形成制御機構の解明」(2007-) 
○「白血病における白血球インテグリンMac-1を介する線容機序」(2001-) 
○「白血病における白血病インテグリンMac-1を介する線溶機序」(2000-) 
○「インテグリンMac-1を介する白血病細胞表面の凝固開始機構」(1997-) 
○「インテグリンMac-1を介する白血病細胞表面の凝固開始機構」(1998-) 

Classes (Bachelors)

○Laboratory Hematology(2017)
○Clinial Practice of Hematology and Blood Transfusion(2017)
○Introduction to Region-studies(2017)
○Lecture and Practice of Hematology(2017)
○Freshman Seminar I(2017)
○Medical English(2017)
○Presentation and Debate (Freshman Seminar II)(2017)
○Presentation and Debate (Freshman Seminar II)(2017)
○Immunology(2017)
○Pathophysiology 1(2017)
○Practice in Laboratory Hematology(2017)
○Laboratory Medicine of Blood Transfusion(2017)
○Immunology(2016)
○Clinial Practice of Hematology and Blood Transfusion(2016)

Classes (Graduate Schools)

○Laboratory Oncology: Lecture(2017)
○Fostering the independence of researchers(2017)
○Advanced Laboratory Oncology: Research(2017)
○Clinical Immunohematology: Lecture(2017)
○An Introduction to Medical Laboratory Sciences:Lec(2017)
○Laboratory Oncology: Research(2017)
○Clinical Immunohematology: Seminar(2017)
○Laboratory Oncology: Seminar(2017)
○Laboratory Oncology: Lecture(2016)
○Advanced Laboratory Oncology: Research(2016)
○Laboratory Oncology: Seminar(2016)
○Clinical Immunohematology: Lecture(2016)
○Laboratory Oncology: Research(2016)
○An Introduction to Medical Laboratory Sciences:Lec(2016)
○Clinical Immunohematology: Seminar(2016)
○Research Design in Health Science: Lecture(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top